Bio-Rad Laboratories News

Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Reported, And Analysts Assigned A US$394 Price Target

Last week saw the newest quarterly earnings release from Bio-Rad Laboratories, Inc. (NYSE:BIO), an important milestone in the company's journey to build a stronger business. The analysts typi

Simply Wall StMay 12 20:19

Bio-Rad Laboratories | 10-Q: Quarterly report

Futu NewsMay 9 04:38 · Announcements

UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating

Bio-Rad Laboratories (BIO) has an average outperform rating and price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 271.46, Change: -8.45, Percent Change: -3.02

MT NewswiresMay 8 22:19

Bio-Rad Laboratories Is Maintained at Buy by UBS

Bio-Rad Laboratories Is Maintained at Buy by UBS

Dow JonesMay 8 21:37

Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS

Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS

Dow JonesMay 8 21:37

UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $385

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $420 to $385.

BenzingaMay 8 21:15

Bio-Rad Laboratories Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 38.34% UBS $420 → $385 Maintains Buy 04/03/2024 31.15% Citigroup $400 → $365 Downgrades Buy → N

BenzingaMay 8 21:14

RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420

Bio-Rad Laboratories (BIO) has an average outperform rating and a price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 277.00, Change: -2.91, Percent Change: -1.04

MT NewswiresMay 8 20:27

Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365

07:37 AM EDT, 05/08/2024 (MT Newswires) -- Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365 Price: 279.11, Change: -0.80, Percent Change: -0.29

MT NewswiresMay 8 19:37

Analysts Are Bullish on These Healthcare Stocks: Bio-Rad Laboratories (BIO), Caribou Biosciences (CRBU)

TipRanksMay 8 18:40

Earnings Call Summary | Bio-Rad Laboratories(BIO.US) Q1 2024 Earnings Conference

The following is a summary of the Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript:Financial Performance:Bio-Rad reported a decrease in Q1 2024 net sales to $611 million, largely due

Futu NewsMay 8 14:59 · Conference Call

Research Alert: CFRA Retains Hold Opinion On Shares Of Bio-rad Laboratories, Inc.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our target to $290 from $360, 24.

MT NewswiresMay 8 06:20

Bio-Rad Laboratories Inc (BIO) Q1 2024 Earnings: Mixed Results Amid Market Challenges

Yahoo FinanceMay 8 05:36

Bio-Rad Laboratories Q1 Non-GAAP Earnings, Revenue Decline

Bio-Rad Laboratories (BIO) reported Q1 non-GAAP net income Tuesday of $2.29 per diluted share, down from $3.34 a year earlier. Four analysts polled by Capital IQ expected $2.14 per share. Revenue for

MT NewswiresMay 8 05:05

Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 Revenue $610.8M, Vs. Street Est of $620.1M

04:24 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 Revenue $610.8M, vs. Street Est of $620.1M

MT NewswiresMay 8 04:24

Bio-Rad Maintains Its FY24 Financial Outlook

The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated non-GAAP operating margin of approximately 13.5 to 14.0 percent.

BenzingaMay 8 04:24

Bio-Rad Laboratories 1Q EPS $13.45 >BIO

Bio-Rad Laboratories 1Q EPS $13.45 >BIO

Dow JonesMay 8 04:21

Bio-Rad Laboratories Q1 2024 Adj EPS $2.29 Beats $2.15 Estimate, Sales $610.820M Miss $619.092M Estimate

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $2.15 by 6.51 percent. This is a 31.44 percent decrease over earnings of $3.

BenzingaMay 8 04:16

Press Release: Bio-Rad Reports First-Quarter 2024 Financial Results

Bio-Rad Reports First-Quarter 2024 Financial Results HERCULES, Calif.--(BUSINESS WIRE)--May 07, 2024-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and

Dow JonesMay 8 04:15

Molecular Weight Marker Market Forecast Report 2019-2029, Featuring Bio-Rad Laboratories, Merck, New England Biolabs, Promega, QIAGEN, VWR, Takara Bio, HiMedia Laboratories and GeneDireX

Yahoo FinanceMay 7 16:03